Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status
about
Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cellsSynergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cellsIndividualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cellsSelection of internal references for qRT-PCR assays of human hepatocellular carcinoma cell lines.Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation.Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma
P2860
Q35902144-A9C65AFE-6A36-4667-B7D9-1C60D683238EQ37613829-C3C4DA55-DE5A-422E-98C3-D53A76BAEF73Q37706060-B11DB013-3AC3-40A2-93FF-01006E347B34Q38296989-2BD46F54-6383-43CF-A588-FD8EA44FB39EQ38812002-5B97D4F3-0664-469B-87F9-71103E637A18Q38850608-C31EE375-B9D2-4F7E-851D-EE4765DC42A7Q38886490-7FFABE20-DB36-4F7E-871F-B7C96F5F0D40Q39819844-72534A7E-C473-4301-A0E0-90A90071B3A7Q39934280-0DC4AEE8-85CB-4007-96AD-7C8284C77F81Q40153668-8EC80422-153D-42C6-B830-9F1306FEB110Q42038363-6A4815EC-CE94-43AE-A545-6065F50ABA7BQ47123408-4C51D553-DD51-490E-ABB5-C453309C6920Q52778675-387EFF34-A33B-4DBA-A604-A1DA4C6A292CQ55383145-D13244C1-9854-4572-8297-04E1390B1068Q58701446-3E101DDA-A399-4BA6-8873-6686D070E1DE
P2860
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sorafenib inhibits intracellul ...... igin or BRAF mutational status
@ast
Sorafenib inhibits intracellul ...... igin or BRAF mutational status
@en
type
label
Sorafenib inhibits intracellul ...... igin or BRAF mutational status
@ast
Sorafenib inhibits intracellul ...... igin or BRAF mutational status
@en
prefLabel
Sorafenib inhibits intracellul ...... igin or BRAF mutational status
@ast
Sorafenib inhibits intracellul ...... igin or BRAF mutational status
@en
P2093
P2860
P1433
P1476
Sorafenib inhibits intracellul ...... igin or BRAF mutational status
@en
P2093
Dagmar Fuhrer
Klaus Mann
Kurt Werner Schmid
Martin Britten
Martina Broecker-Preuss
Stefan Müller
P2860
P2888
P356
10.1186/S12885-015-1186-0
P407
P577
2015-03-26T00:00:00Z
P5875
P6179
1001852460